Airis Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 18-06-2024
- Paid Up Capital ₹ 7.52 Cr
as on 18-06-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 261.33%
(FY 2022)
- Profit 414.86%
(FY 2022)
- Ebitda 1163.57%
(FY 2022)
- Net Worth 4.65%
(FY 2022)
- Total Assets -3.30%
(FY 2022)
About Airis Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 7.52 Cr, as per Ministry of Corporate Affairs (MCA) records.
Srilalitha Bhattaram, Ajoy Yerakaliah, Mohan Patalolla, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2013PTC089550
- Company No.
089550
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Quthbullapur Mandal, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Airis Pharma?
Executive Team (1)
GK
Ganji Kumar
Managing DirectorAppointment Date: 30-Aug-2013
Status: Current
Board Members(6)
Financial Performance and Corporate Structure Insights of Airis Pharma.
Airis Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 261.33% increase. The company also saw a substantial improvement in profitability, with a 414.86% increase in profit. The company's net worth moved up by a moderate rise of 4.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Airis Pharma?
In 2022, Airis Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Smart Agro Industries Corporation Private Limited
Active
15 years 7 months Mohan Patalolla is a mutual person
Smart Agro Food Park Private Limited
Active 10 years 4 months Mohan Patalolla and Ganji Kumar are mutual person
Hyderabad Angels Forum For Entrepreneurship Development
Active 12 years 3 months Ganji Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Airis Pharma?
Airis Pharma has a workforce of 47 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Jun 02, 2023, Airis Pharma has raised a total of ₹ 70.62 Cr, with the most recent deal valued at ₹ 2.4 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
